Dr Kristian Sandberg suggested as new board member

Press release Februari 18, 2020 The board of directors of Lipum AB has suggested Dr Kristian Sandberg to be elected as new member of the board at an extraordinary general meeting held in Umeå on March 3, 2020. Lipum has identified bile salt-stimulated lipase (BSSL) as a novel target for treatment of chronic inflammatory diseases. [...]

2020-02-18T08:00:03+01:00

Professor Anders Fasth joins the scientific advisory board

Press release November 29, 2019 Lipum has developed a biological drug candidate for treatment of chronic inflammatory diseases and aim for a better treatment of juvenile idiopathic arthritis (JIA), that affects children. Therefore, the scientific advisory board of the company is now strengthened with Anders Fasth, senior professor of pediatric immunology at the University of [...]

2020-06-26T11:16:43+02:00

Lipum and Abzena sign integrated CMC agreement

Press release march 19 2019 Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory [...]

2020-06-26T11:13:35+02:00

Umeåföretag tar nästa steg mot ett nytt läkemedel

Pressrelease 3 juni, 2019 Ladda ned pressrelase: Investerare satsar 25 MSEK på nytt läkemedel (pdf) » Umeåföretaget Lipum utvecklar ett biologiskt läkemedel för behandling av kroniska inflammationer. Tidigare pre-kliniska studier har visat mycket goda resultat och potential att ge en bättre behandling av till exempel ledgångsreumatism. ”Konkurrensen i branschen är hård så när vi nyligen [...]

2020-06-26T11:19:43+02:00

Lipum receives 2.2 M€ grant from Horizon 2020

Press release Aug 29, 2018 Lipum's unique approach for treatment of chronic inflammatory diseases receives 2.2 M€ support from EU Horizon 2020, the EU framework program for research and development, will grant 2.2 million euros to Lipum’s ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases. Lipum has identified the novel target [...]

2020-06-26T11:20:54+02:00

Dr Einar Pontén the new CEO at Lipum AB

Press release Dec 29, 2016 The Board of Directors of Lipum AB in Umeå has appointed Dr Einar Pontén new CEO. "We are very pleased to recruit an experienced force when Lipum face a very exciting development," said Chairman Ulf Björklund. Link to Press release in Swedish»  

2020-06-26T11:22:00+02:00
Till toppen